Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group

Ralf‐Dieter Hofheinz(University of Mannheim), Andreas Schneeweiß(German Cancer Research Center), Deniz Gencer(Heidelberg University), Luisa Mantovani Loeffler(Heidelberg University), Jochem Potenberg(Heidelberg University), H. Schulz(Uni Research (Norway)), Felix Tauchert(Heidelberg University), Ursula Kronawitter(Heidelberg University), Susanna Hegewisch‐Becker, Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Georg Bolz(Heidelberg University)
Journal of Clinical Oncology
June 30, 2015
10.1200/jco.2014.60.4587
Cited by 82

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784